BR112022003581A2 - Vetor de expressão contra o vírus da síndrome respiratória aguda grave sars-cov-2 - Google Patents

Vetor de expressão contra o vírus da síndrome respiratória aguda grave sars-cov-2

Info

Publication number
BR112022003581A2
BR112022003581A2 BR112022003581A BR112022003581A BR112022003581A2 BR 112022003581 A2 BR112022003581 A2 BR 112022003581A2 BR 112022003581 A BR112022003581 A BR 112022003581A BR 112022003581 A BR112022003581 A BR 112022003581A BR 112022003581 A2 BR112022003581 A2 BR 112022003581A2
Authority
BR
Brazil
Prior art keywords
seq
expression vector
adenovirus serotype
cov
acute respiratory
Prior art date
Application number
BR112022003581A
Other languages
English (en)
Inventor
Vadimovna Zubkova Olga
Andreevna Ozharovskaia Tatiana
Vadimovna Dolzhikova Inna
Popova Olga
Viktorovich Shchebliakov Dmitrii
Mikhailovna Grousova Daria
Shahmirovna Dzharullaeva Alina
Ildarovich Tukhvatulin Amir
Mikhailovna Tukhvatulina Natalia
Nikolaevich Shcherbinin Dmitrii
Bulatovich Esmagambetov Ilias
Alexsandrovna Tokarskaya Elizaveta
Gennadevich Botikov Andrei
Sergeevna Eroxova Alina
Anatolevna Nikitenko Natalya
Vladimirovich Borisevich Sergey
Sergeevich Semikhin Aleksandr
Yuryevich Logunov Denis
Savelievich Naroditsky Boris
Leonidovich Gintsburg Aleksandr
Original Assignee
Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020127979A external-priority patent/RU2731356C9/ru
Application filed by Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte filed Critical Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Publication of BR112022003581A2 publication Critical patent/BR112022003581A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

VETOR DE EXPRESSÃO CONTRA O VÍRUS DA SÍNDROME RESPIRATÓRIA AGUDA GRAVE SARS-COV-2. A presente invenção refere-se à biotecnologia, imunologia e virologia. Cria-se um vetor de expressão contendo o genoma do sorotipo 26 de adenovírus humano recombinante, em que as regiões E1 e E3 são deletadas, e a região ORF6-Ad26 é substituída por ORF6-Ad5, com um cassete de expressão integrado selecionado de SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 (variante 1). Assim, a sequência SEQ ID NO: 5 é usada como uma sequência parental do sorotipo 26 de adenovírus humano. No mais, cria-se um vetor de expressão contendo o genoma de adenovírus símio recombinante sorotipo 25, em que as regiões E1 e E3 são deletadas, com um cassete de expressão integrado selecionado de SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 (variante 2). A sequência SEQ ID NO: 6 é usada como uma sequência parental do sorotipo 25 de adenovírus símio. Ademais, cria-se um vetor de expressão contendo o genoma do sorotipo 5 de adenovírus humano recombinante, em que as regiões E1 e E3 são deletadas, com um cassete de expressão integrado selecionado de SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 (variante 3). Assim, a sequência SEQ ID NO: 7 foi usada como uma sequência parental do sorotipo 5 de adenovírus humano. A invenção também se refere ao método de uso do vetor de expressão desenvolvido para criar um agente imunobiológico para induzir a imunidade específica contra o vírus da síndrome respiratória aguda grave SARS-CoV-2.
BR112022003581A 2020-08-22 2020-11-06 Vetor de expressão contra o vírus da síndrome respiratória aguda grave sars-cov-2 BR112022003581A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020127979A RU2731356C9 (ru) 2020-08-22 2020-08-22 Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
PCT/RU2020/000589 WO2021076009A1 (en) 2020-08-22 2020-11-06 Expression vector against severe acute respiratory syndrome virus sars-cov-2

Publications (1)

Publication Number Publication Date
BR112022003581A2 true BR112022003581A2 (pt) 2022-08-16

Family

ID=75262212

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003581A BR112022003581A2 (pt) 2020-08-22 2020-11-06 Vetor de expressão contra o vírus da síndrome respiratória aguda grave sars-cov-2

Country Status (11)

Country Link
US (1) US20220235376A1 (pt)
EP (1) EP4010018A4 (pt)
JP (1) JP7369276B2 (pt)
KR (1) KR20230088301A (pt)
CN (1) CN114845733A (pt)
BR (1) BR112022003581A2 (pt)
CA (1) CA3152658A1 (pt)
EA (1) EA037291B9 (pt)
IL (1) IL291022A (pt)
MX (1) MX2022002609A (pt)
ZA (1) ZA202202322B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113308493A (zh) * 2021-03-18 2021-08-27 广州恩宝生物医药科技有限公司 新型冠状病毒Ad26腺病毒载体疫苗及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251677B1 (en) * 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
CN1342206A (zh) * 1998-08-28 2002-03-27 杜克大学 在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2010037027A2 (en) * 2008-09-26 2010-04-01 Auburn University Immunization of avians by mucosal administration of non-replicating vectored vaccines
US10183069B2 (en) * 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
NZ630649A (en) * 2012-03-22 2016-12-23 Janssen Vaccines & Prevention Bv Vaccine against rsv
GB2549809C (en) * 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
CN111218459B (zh) * 2020-03-18 2020-09-11 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗

Also Published As

Publication number Publication date
MX2022002609A (es) 2022-06-08
ZA202202322B (en) 2023-12-20
CN114845733A (zh) 2022-08-02
EP4010018A1 (en) 2022-06-15
JP2023505920A (ja) 2023-02-14
JP7369276B2 (ja) 2023-10-25
CA3152658A1 (en) 2021-04-22
KR20230088301A (ko) 2023-06-19
EP4010018A4 (en) 2022-11-09
EA202000369A1 (ru) 2021-03-02
EA037291B9 (ru) 2021-11-24
EA037291B1 (ru) 2021-03-05
IL291022A (en) 2022-05-01
EA037291B8 (ru) 2021-04-26
US20220235376A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
BR112018076633A2 (pt) mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿uk
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
BRPI0312173B8 (pt) vetor e processo para a preparação de partículas infecciosas de vírus do sarampo
BR112022014884A2 (pt) Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave
BR112022003581A2 (pt) Vetor de expressão contra o vírus da síndrome respiratória aguda grave sars-cov-2
BR112022004767A2 (pt) Agente para induzir imunidade específica contra o vírus da síndrome respiratória aguda grave sars-cov-2 na forma líquida (variantes)
BR112022006718A2 (pt) Composição farmacêutica e métodos de vetor de vírus adeno-associado
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
PE20090653A1 (es) Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc
BR112021019845A2 (pt) Composições de vírus inativado e formulações de vacina contra zika
BR112021019859A2 (pt) Vacinas de circovírus suíno tipo 3 (pcv3) e produção e seus usos
BR112017013270A2 (pt) ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?.
Solorzano et al. Reduced levels of neuraminidase of influenza A viruses correlate with attenuated phenotypes in mice
BR112022004778A2 (pt) Agente para indução de imunidade específica contra o vírus da síndrome respiratória aguda grave sarscov-2 em forma liofilizada (variantes) e uso
ZA202301438B (en) Aa v5-based vaccine against sars-cov-2
AR125000A1 (es) VECTOR DE EXPRESIÓN PARA EL DESARROLLO DE UN AGENTE INMUNOBIOLÓGICO PARA INDUCIR INMUNIDAD ESPECÍFICA CONTRA EL VIRUS DEL SÍNDROME RESPIRATORIO AGUDO SEVERO SARS-CoV-2 (VARIANTES)
AR124461A1 (es) VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2
BR0016371A (pt) Utilização de uma proteìna proveniente de células cancerosas de células infectadas por um vìrus ou de células imunológicas ou ainda de um fragmento inativo desta proteìna, composição farmacêutica, processo de preparação de uma composição farmacêutica, anticorpo e fragmento de um anticorpo
MX2022003963A (es) El uso del agente para induccion de inmunidad especifica contra virus de sindrome respiratorio agudo severo sars-cov-2 para revacunacion de la poblacion (variantes).
BR112022005920A2 (pt) Uso do agente para indução de imunidade específica contra o vírus da síndrome respiratória aguda grave sarscov-2
MX2022004059A (es) Utilizacion de un agente para la induccion de inmunidad especifica contra el virus del sindrome respiratorio agudo severo sars-cov-2 en ni?os.
BRPI0415784A (pt) composição polipeptìdica antigênica, famìlia de genes purificados, famìlia de polinucleotìdeos, gene de plasmodium falciparum isolado de uma famìlia, seqüência de polinucleotìdeo, proteìna, polipeptìdio antigênico, composições imunogênicas, vacinas, uso de uma proteìna recombinante, anticorpo purificado sintético ou recombinante ou fragmento de anticorpo, conjunto de anticorpos ou fragmentos de anticorpos, uso de uma composição, medicamento, métodos para diagnóstico, kits para diagnóstico, seqüência de nucleotìdeo recombinante, vetor de clonagem e/ou de expressão recombinante, uso de um vetor de expressão e célula hospedeira recombinante
AR124744A1 (es) AGENTE PARA USO EN LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL VIRUS DEL SÍNDROME RESPIRATORIO SEVERO AGUDO SARS-CoV-2 EN SUJETOS MAYORES DE 60 AÑOS DE EDAD Y/O QUE TIENEN ENFERMEDADES CRÓNICAS (VARIANTES)
BR112022003611A2 (pt) Agente farmacêutico para induzir imunidade específica contra sars-cov-2
AR125270A1 (es) AGENTE FARMACÉUTICO Y MÉTODO DE UTILIZACIÓN DEL MISMO PARA INDUCIR INMUNIDAD ESPECÍFICA CONTRA EL VIRUS DEL SÍNDROME RESPIRATORIO AGUDO SEVERO SARS-CoV-2 (VARIANTES)